
Promising Phase 2 obesity data for Novo’s diabetes drug
pharmafile | June 26, 2017 | News story | Research and Development, Sales and Marketing |Â Â Novo NordiskÂ
Novo Nordisk is hopeful about the prospects of its diabetes drug semaglutide as a treatment for obesity after it produced positive results in a Phase 2 trial of 957 participants.
Semaglutide was tested as a treatment to help patients with obesity to induce and maintain weight loss. Administered subcutaneously over 52 weeks, the GLP-1 drug produced a weight loss of up to 13.8%, or 17.8kg, after 52 weeks from an average baseline weight of 111kg and body mass index of 39. This was compared to a loss of just 2.3% via diet, exercise and placebo in absence of semaglutide.
During an interview earlier this year, Novo’s Chief Executive Lars Fruergaard Jorgensen said: “What will really open the obesity market is efficacy. You probably have to get toward 15% for the market to fully open up.”
With these new results, the company could be on to a potential winner in the field. Semaglutide is already being tested in diabetes types 1 and 2, and Novo Nordisk is hoping it can outperform its other obesity drug Saxenda.
“We are very excited about these strong results and the potential of semaglutide as a new treatment for people with obesity,” chief science officer Mads Krogsgaard Thomsen said in a statement. “We will now prepare the phase 3 programme with semaglutide to confirm these results. We expect the Phase 3 programme to begin in 2018.”
Matt Fellows
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …






